These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

131 related items for PubMed ID: 2793413

  • 61. [The concentration of homovanillic acid and leucine-enkephalin in the lumbar CSF of patients with Parkinson's disease before and after madopar treatment].
    Liu DK.
    Zhonghua Shen Jing Jing Shen Ke Za Zhi; 1989 Apr; 22(2):95-8, 126-7. PubMed ID: 2791764
    [Abstract] [Full Text] [Related]

  • 62. Increased life expectancy resulting from addition of L-deprenyl to Madopar treatment in Parkinson's disease: a longterm study.
    Birkmayer W, Knoll J, Riederer P, Youdim MB, Hars V, Marton J.
    J Neural Transm; 1985 Apr; 64(2):113-27. PubMed ID: 3935752
    [Abstract] [Full Text] [Related]

  • 63. Implications of combined treatment with 'Madopar' and L-deprenil in Parkinson's disease. A long-term study.
    Birkmayer W, Riederer P, Ambrozi L, Youdim MB.
    Lancet; 1977 Feb 26; 1(8009):439-43. PubMed ID: 65560
    [Abstract] [Full Text] [Related]

  • 64. Dopamine agonists in clinical research for new tardive dyskinesia treatments.
    Gerlach J, Casey DE.
    Mod Probl Pharmacopsychiatry; 1983 Feb 26; 21():97-110. PubMed ID: 6140637
    [No Abstract] [Full Text] [Related]

  • 65. [Study of the M-H response, of the silent period and of post-tetanic potentiation in subjects with Parkinson's disease during treatment with L-dopa or Madopar].
    Ferro Milone F, Lorizio A, Nordera G.
    Riv Neurol; 1975 Feb 26; 45(2):236-46. PubMed ID: 1179114
    [No Abstract] [Full Text] [Related]

  • 66. Effect of L-dopa on polycythemia.
    Herishanu Y, Rosenberg P.
    J Am Geriatr Soc; 1977 May 26; 25(5):218-9. PubMed ID: 853205
    [Abstract] [Full Text] [Related]

  • 67. [Controlled release levodopa-benserazide and changes in efficacy during treatment of Parkinson's disease].
    Rondot P, Ziegler M, Aymard N, Holzer J.
    Rev Neurol (Paris); 1987 May 26; 143(11):746-52. PubMed ID: 3324265
    [Abstract] [Full Text] [Related]

  • 68. Report on 45-month treatment of parkinsonism with L-dopa, alone and in association with a decarboxilase inhibitor (Ro 4-4602).
    Chouza C, Romero S, Gomensoro JB.
    Acta Neurol Latinoam; 1974 May 26; 20(1-4):116-38. PubMed ID: 4619960
    [No Abstract] [Full Text] [Related]

  • 69. [Results of prolonged treatment of Parkinson's disease with the L-dopa-benserazide combination].
    Casacchia M, Barba C, Ruggieri S, Zamponi A, Agnoli A.
    Riv Neurol; 1974 May 26; 44(5):303-30. PubMed ID: 4217465
    [No Abstract] [Full Text] [Related]

  • 70. Levodopa alone and in combination with a peripheral decarboxylase inhibitor benserazide (Madopar) in the treatment of Parkinson's disease: A controlled clinical trial.
    Rinne UK, Birket-Smith E, Dupont E, Hansen E, Hyyppä M, Marttila R, Mikkelsen B, Pakkenberg H, Presthus J.
    J Neurol; 1975 Dec 02; 211(1):1-9. PubMed ID: 56427
    [Abstract] [Full Text] [Related]

  • 71. Mortality among Parkinson patients treated with L-dopa combined with a decarboxylase inhibitor.
    Zumstein H, Siegfried J.
    Eur Neurol; 1976 Dec 02; 14(5):321-8. PubMed ID: 949985
    [Abstract] [Full Text] [Related]

  • 72. Correlation of clinical symptoms, HVA and 5-HIAA in csf and plasma L-DOPA in Parkinsonian patients treated with L-DOPA and L-DOPA + RO 4-4602.
    Campanella G, Algeri S, Cerletti C, Dolfini E, Jori A, Rinaldi F.
    Eur J Clin Pharmacol; 1977 Apr 20; 11(4):255-61. PubMed ID: 862646
    [No Abstract] [Full Text] [Related]

  • 73. The clinical efficacy of oral levodopa methyl ester solution in reversing afternoon "off" periods in Parkinson's disease.
    Steiger MJ, Stocchi F, Carta A, Ruggieri S, Agnoli A, Quinn NP, Marsden CD.
    Clin Neuropharmacol; 1991 Jun 20; 14(3):241-4. PubMed ID: 2070364
    [Abstract] [Full Text] [Related]

  • 74. Pharmaceutical review: salbutamol - madopar - isocal.
    Martin S.
    Lamp; 1978 Mar 20; 35(3):34-9. PubMed ID: 418280
    [No Abstract] [Full Text] [Related]

  • 75. [Madopar in the treatment of paralysis agitans. I. Therapeutic efficacy and side-effects in 56 cases (author's transl)].
    Liu DK.
    Zhonghua Shen Jing Jing Shen Ke Za Zhi; 1980 Mar 20; 13(3):147-50. PubMed ID: 7438902
    [No Abstract] [Full Text] [Related]

  • 76. [Development of studies on the treatment of parkinsonian syndromes with levodopa. II. Long-term effects of L-DOPA alone or in combination with a decarboxylase inhibitor].
    Rabadeau Dumas JL, Rondot P, Cardon P.
    Therapie; 1977 Mar 20; 32(2):161-72. PubMed ID: 898124
    [No Abstract] [Full Text] [Related]

  • 77. Thyrotrophin and prolactin responses to thyrotrophin-releasing hormone in patients with Parkinson's disease.
    Martinez-Campos A, Giovannini P, Novelli A, Cocchi D, Caraceni T, Müller EE.
    Acta Endocrinol (Copenh); 1982 Mar 20; 99(3):344-51. PubMed ID: 6803485
    [Abstract] [Full Text] [Related]

  • 78. Combined use of benserazide and carbidopa in Parkinson's disease.
    Lieberman AN, Goldstein M, Gopinathan G, Neophytides A, Hiesiger E, Walker R, Nelson J.
    Neurology; 1984 Feb 20; 34(2):227-9. PubMed ID: 6538015
    [Abstract] [Full Text] [Related]

  • 79. [Improvement with the combination of L-dopa and benserazide of postural dysregulations of the cerebral circulation: preliminary study].
    Boismare F, Boquet J, Lefrançois J, Le Poncin M.
    Agressologie; 1977 Feb 20; 18(5):285-6. PubMed ID: 602991
    [No Abstract] [Full Text] [Related]

  • 80.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.